Oncimmune has been contracted by a global pharmaceutical leader to study autoantibody profiling of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).
Oncimmune, the immunodiagnostics company, is using their ImmunoINSIGHTS autoantibody profiling service to understand autoimmune illness and infectious diseases.
SeroTag Infectious Diseases discovery array allows scientists to better understand how SARS-CoV-2 triggers an immune response and forecast how vaccines and treatments for the virus will work using the group’s proprietary biomarker discovery platform.
CIDP is an autoimmune illness that targets the myelin sheaths, which are the fatty coatings that insulate and protect nerves. In its acute phase, CIDP is commonly referred to as Guillain-Barré syndrome, but it is chronic, difficult to diagnose, and can result in irreversible physical damage if not treated early on.
For the new contract, Oncimmune will use SertoTag to discover autoantibodies with a connection to CIDP. Using ImmunoINSIGHTS, the firm can manufacture specific antigens associated with CIDP via the group’s SeroTag platform. SeroTag will screen tests from patients with CIDP to find autoantibodies with relevance.
Dr. Adam M Hill, Chief Executive Officer, Oncimmune commented,”We are pleased to announce this contract with another leading pharmaceutical company, adding to the growing list of global partners, working with us in the rare disease space where there is a real clinical need and opportunity to make a significant impact.”
“This contract will make full use of the unique attributes of our SeroTag platform, and the competencies amongst our scientific colleagues, who are world leaders in autoimmune profiling.”
“As is typical with SeroTag contracts, there is potential for the initial discovery work in autoantibodies to progress to further research and support for therapeutic development, creating and refining CIPD-specific NavigAID panels using additional data and markers to guide drug development and inform patient and disease stratification.”